Morvil Narmadha, Wong Hei Man
Department of Infectious Diseases, Singapore General Hospital, The Academia, Level 3, 20 College Rd, Singapore, 169856, Singapore.
BMC Infect Dis. 2025 Jul 1;25(1):853. doi: 10.1186/s12879-025-11188-8.
Candida viswanathii is a rare Candida with fewer than 40 clinical cases of infection reported globally and with limited treatment descriptions available. Here we report a rare case of recurrent candida septic arthritis and osteomyelitis caused by C. viswanathii.
A 78-year-old Chinese female developed her first episode of C. viswanathii septic arthritis and osteomyelitis likely following intra-articular lignocaine injections to her left knee. She was treated with 2 surgical washouts and 16 months of antifungal agents, which included an initial 6 months of voriconazole followed by fluconazole, with full recovery. However, she presents with recurrence of left knee pain 14 months after antifungal therapy was stopped. Open arthrotomy revealed extensive synovitis and granulation tissue, with a sinus tract extending to the anterior patella. C. viswanathii was re-cultured in her synovial fluid and identified via a combination of fungal phenotypic tests and DNA sequencing of the ITS region and the D1/D2 region of the 28 S ribosomal subunit. She was managed with two open knee arthrotomies, drainage with curettage and debridement, and was reinitiated on oral voriconazole therapy, to which she demonstrated a good clinical response. She was subsequently maintained on chronic suppressive oral voriconazole therapy. Her symptoms remain well controlled, and no relapse was observed on the last follow-up. Additionally, we have also done a comprehensive literature review of all the published clinical cases of C. viswanathii thus far.
This is the first case report to describe the successful treatment and monitoring of recurrent C. viswanathii osteoarticular infection. Combined with our literature review, we aim to increase understanding of this rare candida species- specifically its clinical trajectory in osteoarthritic infections, laboratory features, radiological characteristics, intra-operative findings, and treatment aspects inclusive of a potential role for long-term suppressive therapy.
维斯瓦纳森念珠菌是一种罕见的念珠菌,全球报告的感染临床病例少于40例,且可用的治疗描述有限。在此,我们报告一例由维斯瓦纳森念珠菌引起的复发性念珠菌性败血症性关节炎和骨髓炎的罕见病例。
一名78岁的中国女性,在左膝关节腔内注射利多卡因后,首次发生维斯瓦纳森念珠菌性败血症性关节炎和骨髓炎。她接受了2次手术冲洗和16个月的抗真菌药物治疗,最初6个月使用伏立康唑,随后使用氟康唑,最终完全康复。然而,在抗真菌治疗停止14个月后,她再次出现左膝疼痛。开放性关节切开术显示广泛的滑膜炎和肉芽组织,有一个窦道延伸至髌骨前部。在她的滑液中再次培养出维斯瓦纳森念珠菌,并通过真菌表型试验以及对28S核糖体亚基的ITS区域和D1/D2区域进行DNA测序进行鉴定。她接受了两次开放性膝关节切开术、刮除术和清创引流,并重新开始口服伏立康唑治疗,临床反应良好。随后她继续接受慢性口服伏立康唑抑制治疗。她的症状得到很好的控制,在最后一次随访中未观察到复发。此外,我们还对迄今为止所有已发表的维斯瓦纳森念珠菌临床病例进行了全面的文献综述。
这是第一例描述成功治疗和监测复发性维斯瓦纳森念珠菌骨关节感染的病例报告。结合我们的文献综述,我们旨在增进对这种罕见念珠菌的了解,特别是其在骨关节炎感染中的临床病程、实验室特征、放射学特征、术中发现以及治疗方面,包括长期抑制治疗的潜在作用。